Drug & intervention
durvalumab
RxCUI 1919503
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
40 shownA Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCNCT07459634 · 2026-11-30
RECRUITINGFutibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerNCT07710885 · 2026-06-24
RECRUITINGStudy of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerNCT07339059 · 2026-05-14
RECRUITINGStudy of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)NCT07531095 · 2026-04-21
RECRUITINGA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)NCT07361497 · 2026-03-16
RECRUITINGBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsNCT07195695 · 2026-01-16
RECRUITINGInvestigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerNCT06954480 · 2025-10-27
RECRUITINGA Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerNCT07174583 · 2025-10-14
RECRUITINGTargeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)NCT06564623 · 2025-05-27
RECRUITINGStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerNCT06890598 · 2025-03-27
RECRUITINGHepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)NCT06859684 · 2025-03-01
RECRUITINGStudy of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC PatientsNCT06634199 · 2024-10-03
RECRUITINGA Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast CancerNCT06508216 · 2024-07-05
RECRUITINGA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)NCT06103864 · 2023-11-23
RECRUITINGDurvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLCNCT06223711 · 2023-10-06
RECRUITINGMOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerNCT05903092 · 2023-09-26
RECRUITINGQuick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung CancerNCT05696782 · 2023-07-26
RECRUITINGDurvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)NCT06371482 · 2023-06-01
RECRUITINGLK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung CancerNCT05886439 · 2023-05-11
RECRUITINGTRUDI: TDXD+Durva in HER2+/Low IBCNCT05795101 · 2023-05-04
RECRUITINGImmunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCNCT05720260 · 2023-01-17
RECRUITINGREStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)NCT05632809 · 2023-01-10
RECRUITINGRestoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelNCT05582538 · 2022-12-15
RECRUITINGDurvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)NCT05068232 · 2022-08-19
RECRUITINGRandomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and DurvalumabNCT05568212 · 2022-05-02
RECRUITINGNeoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerNCT05061550 · 2022-04-14
RECRUITINGAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCNCT04585490 · 2021-08-25
RECRUITINGA Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCNCT04550104 · 2021-03-17
RECRUITINGDurvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung CancerNCT04499053 · 2020-12-09
RECRUITINGPHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerNCT03740893 · 2019-10-15
RECRUITINGTarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung CancerNCT07637513 · 2027-01-01
NOT_YET_RECRUITINGPersonnalized Immunotherapy in Patients With Stage III Non-small Cell Lung CancerNCT07759492 · 2026-11-01
NOT_YET_RECRUITINGNeoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)NCT06694454 · 2026-10-12
SUSPENDEDStudy for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)NCT07247786 · 2026-09-15
NOT_YET_RECRUITINGThe Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2NCT07146230 · 2026-09-01
NOT_YET_RECRUITINGA Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)NCT07672223 · 2026-06-25
NOT_YET_RECRUITINGDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.NCT06992609 · 2025-09-15
ACTIVE_NOT_RECRUITINGA Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)NCT07005128 · 2025-08-18
ACTIVE_NOT_RECRUITINGNeoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLCNCT06998719 · 2025-07-01
NOT_YET_RECRUITINGStudy of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )NCT06939036 · 2025-07-01
TERMINATEDConditions being studied
Non-Small Cell Lung Cancer36Breast Cancer17Lung Cancer15Carcinoma, Non-Small-Cell Lung14Non Small Cell Lung Cancer14Extensive-stage Small-cell Lung Cancer8Nsclc8Small Cell Lung Cancer8Small-cell Lung Cancer8Non-small Cell Lung Cancer (NSCLC)7Metastatic Breast Cancer6NSCLC, Stage III6Small Cell Lung Carcinoma6Non-small Cell Lung Cancer Stage III5Triple Negative Breast Cancer5Non-small Cell Lung Cancer Stage I4Prostate Cancer4Durvalumab3Extensive Stage Small Cell Lung Cancer3Extensive-stage Small Cell Lung Cancer3
Research locations
Leading sponsors
AstraZeneca47Ludwig Institute for Cancer Research6Memorial Sloan Kettering Cancer Center6Amgen5Canadian Cancer Trials Group4Gustave Roussy, Cancer Campus, Grand Paris4National Cancer Institute (NCI)4UNICANCER4Fundación GECP3Intergroupe Francophone de Cancerologie Thoracique3M.D. Anderson Cancer Center3MedImmune LLC3PrECOG, LLC.3Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3Swiss Cancer Institute3
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.